Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The approval adds a new indication for GLP-1 drugs and gives Novo an advantage over Lilly’s rival diabetes drug Mounjaro, ...

Novo Nordisk A/S’s blockbuster Ozempic won US approval to treat chronic kidney disease in patients who also have type 2 ...

A popular diabetes drug just got a major new approval -- and it could be a game-changer for millions of Americans a ...

Ozempic was first approved by the FDA in 2017 for blood sugar control in Type 2 diabetes. It received a cardiovascular indication in 2020 and is now the most broadly indicated GLP-1 receptor agonist ...

Last year, a friend found an Ozempic pen left behind in the fridge at her Paris hotel room during the city’s Fashion Week It doesn’t help that there has been an avalanche of stories about ...

The current list price for Ozempic is $968.52 per pen without insurance. While this drug can be expensive, Novo Nordisk offers a savings card for those with commercial or private insurance who are ...

A class of drugs designed to fight diabetes and weight loss can help with a host of other problems, but also carry some side effects.